Compare SCD & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | CERS |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 276.0M |
| IPO Year | N/A | 1997 |
| Metric | SCD | CERS |
|---|---|---|
| Price | $14.88 | $1.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 62.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $11.33 | $1.12 |
| 52 Week High | $15.87 | $2.24 |
| Indicator | SCD | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 72.10 |
| Support Level | $14.65 | $1.71 |
| Resistance Level | $14.94 | $1.78 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 93.04 | 94.50 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.